Project Grant R01HL183395
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $781,860 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of neutrophils in mediating endothelial regeneration and vascular repair in sepsis and acute respiratory distress syndrome (ARDS). The research addresses ARDS pathology, specifically endothelial barrier injury and increased vascular...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $360,418 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe classifiers for diagnosing lower respiratory tract infection in children using metagenomic next-generation sequencing applied to non-invasive samples including nasopharyngeal swabs and whole blood. The project addresses diagnostic gaps in pediatric...
- The National Heart, Lung, and Blood Institute awarded Seattle Children's Hospital $930,637 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to conduct PROSPER (Pulmonary Recovery and Outcomes After Severe Pediatric Respiratory Illness), a multicenter prospective longitudinal cohort study examining how impaired pulmonary function contributes to physical and health-related quality-of-life morbidity among children surviving acute respiratory failure. The...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $509,622 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate novel ultrasound techniques for assessing right ventricular diastolic dysfunction in children with pulmonary arterial hypertension. The project conducts a prospective two-center observational cohort study combining conventional ultrasound and ultrafast ultrasound (UFUS) imaging...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $438,328 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support the Pediatric Acute Care Research (PACER) Training Program. The PACER program provides postdoctoral scholars with mentored, experiential research opportunities, didactics, seminars, apprenticeships, and career development experiences in pediatric emergency and critical care medicine....
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $126,518 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to build a patient-oriented research mentoring program in human neonatal and infant airway biology. The award funds mentoring and research addressing mechanisms regulating airway epithelial immune responses in early life, with particular focus on populations historically excluded from respiratory research: infants with...
- The National Institutes of Health National Heart Lung and Blood Institute awarded New York University $201,728 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research examining mechanisms contributing to functional recovery across the care cascade for respiratory failure. The research addresses how patient-level social determinants recorded at hospital admission, unit-level care processes during hospitalization, and community-level environmental...
The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical ventilation and track acute respiratory infection outcomes over 12 months. The study aims to identify modifiable factors—including parental self-efficacy in managing complex home care regimens and vital sign monitoring practices—that influence clinical decision-making, treatment selection, triage, and progression to emergency department visits or hospitalization. Preliminary work has established wide variation in care and outcomes in this population, despite acute respiratory infection being the leading cause of death and hospitalization among children on long-term home mechanical ventilation, with annual mortality of 5 percent. The research will standardize monitoring of physiologic changes at home to improve child and family outcomes and reduce healthcare costs and institutional utilization. Work is performed in Chicago, Illinois. The period of performance extends from September 1, 2026, to May 31, 2031. The assistance type is a Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $876.6k | 8/27/26 |